PubRank
Search
About
Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases (OPTIMAL)
Clinical Trial ID NCT04001725
PubWeight™ 0.00
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT04001725
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Hallmarks of cancer: the next generation.
Cell
2011
140.01
2
Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.
J Thorac Cardiovasc Surg
2003
5.33
3
Long-term metformin use is associated with decreased risk of breast cancer.
Diabetes Care
2010
3.68
4
Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis.
Am J Epidemiol
2014
3.49
5
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Cancer
2004
2.30
6
Metformin prevents metabolic side effects during systemic glucocorticod treatment.
Eur J Endocrinol
2017
1.43
7
A guide to immunometabolism for immunologists.
Nat Rev Immunol
2016
1.41
8
Treatment of Brain Metastases.
J Clin Oncol
2015
1.03
9
Glucocorticoid-induced hyperglycemia.
Am J Med Sci
2013
0.94
10
How to manage steroid diabetes in the patient with cancer.
J Support Oncol
2006
0.89
11
Glucocorticoid-induced hyperglycemia.
J Diabetes
2013
0.85
12
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.
Cancer Discov
2016
0.82
13
Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study.
Curr Oncol
2013
0.79
14
Safety and efficacy of metformin for therapy-induced hyperglycemia in children with acute lymphoblastic leukemia.
J Pediatr Hematol Oncol
2013
0.79
15
Optimizing the Treatment of Steroid-Induced Hyperglycemia.
Ann Pharmacother
2017
0.75
16
MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.
J Exp Clin Cancer Res
2017
0.75
Next 100